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GENETIC CHARACTERIZATION OF THE, K2 SEROTYPE CAPSUL.E OF 
KLEBSIELLA PNEUMONIAE ATCC 43816 AND THE DEVELOPME~IT OF A 
BIOLUMINESCENT STRAIN 
Jacob Brandon Scott 
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OBJECTIVE: Klebsiella pneumoniae is a Gram-negative enterobacterium that is 
a major cause of community-acquired and nosocomial infections. We performed 
a genetic characterization of K. pneumoniae strain ATCC 43816, which is a well-
studied strain with a K2 serotype capsular polysaccharide. To provide thl~ ability 
to monitor bacteria within a host, we will develop a bioluminescence stra n of K. 
pneumoniae by integrating the lux operon into the chromosome. METHODS: The 
ATCC 43816 capsule cluster sequencing was performed by closing gapE, in the 
Next Generation Sequencing by long range peR for template and primer 
walking. We constructed a bioluminescent K. pneumoniae by using allelit:: 
exchange strategies and subsequently characterized the bioluminescent strain 
JSKP001 in a macrophage infection model. RESULTS: We have sequerced and 
annotated the CPS cluster as a 23,804-base pair sequence and identified eight 
homologous genes conserved between all serotypes of Klebsiella. Using our 
v 
bioluminescent strain JSKP001, we demonstrate that K. pneumoniae may enter 
a reduced metabolic state within macrophages. CONCLUSION: We havH 
successfully sequenced and annotated a K2 serotype CPS cluster with high 
homology to other K2 serotypes K. pneumoniae strains. We observed that K. 
pneumoniae is internalized by macrophages, but proliferates at a slow rate. We 
tested our bioluminescent strain in numerous growth conditions and found that 
rich growth media supports higher metabolic activity while the lowest activity was 
detected in K. pneumoniae internalized within rnacrophages. This suggeBts that 
macrophages may only provide a minor role as an intracellular replicativE! niche 
in vivo, but might be a potential niche for chronic persistence in sublethal 
infections. 
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It has been less than 140 years since our understanding of the ability of 
bacteria to cause lethal pneumonia was first established from the combined 
efforts of Edwin Klebs and Carl Friedlander in the late 19th century [1, 2]. It was 
in Friedlander's laboratory where Hans Christian Gram developed the "GI-am 
stain" technique to detect bacteria in histological sections of the mammalian lung 
[3]. This technique stains bacteria one of two colors: Gram-positive (purple/blue) 
and Gram-negative (pink/red), of which Klebsiella pneumoniae was the first 
identified as a Gram-negative organism, distinguished from the previousl)' 
observed Gram-positive Streptococcus pneumoniae [4]. 
1.2 Epidemiology 
K. pneumoniae subsp_ pneumoniae (K. pneumoniae) is a Gram-negative, 
non-motile, encapsulated, rod-shaped bacterial pathogen that is ubiquitollsly 
found in nature as well as mucosal surfaces of animals [5]. K. pneumoniae is an 
opportunistic pathogen that primarily infects imrnunocompromised individuals 
with underlying or pre-existing health conditions such as diabetes mellitus, 
alcoholism, and chronic pulmonary obstructions_ As an opportunistic path:>gen, 
K. pneumoniae is responsible for causing a wide-range of infections from urinary 
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tract infections (UTI's), septicemia, intestinal infections, wound infections and 
pneumonia [6, 7]. Furthermore, antibiotic resistant K. pneumoniae is a si!~nificant 
contributor to nosocomial and community-acqUlired infections worldwide 18, 9]. 
1.2.1 Nosocomial Infections 
K. pneumoniae has been described as the 7th most frequently cultured 
clinical isolate overall in U.S. hospitals [10] and the 4th overall in European 
hospitals [11]. The two most common presentations of K. pneumoniae in 
hospitals are in the airway and urinary tract infections, frequently associated with 
the use of contaminated medical devices such as endotracheal tubes or 
catheters (Frank et aI., 2009; Jones, 2010). Since the 1970's, K. pneumoniae 
nosocomial infections in westernized hospitals have become increasingly 
associated with resistance to aminoglycoside antibiotics allowing for incmased 
persistence within the health care setting [12]. However, in recent years )( 
pneumoniae strains have acquired plasmid-based extended-spectrum 13-
lactamases (ESBLs) [13], which convey resistance against newer 
cephalosporins. Currently, carbapenem antibiotics (imipenem and meropenem) 
are the most effective antibiotics against Gram··negative, respiratory-assc,ciated 
infections [14]. Consistent with the ability of K. pneumoniae to acquire antibiotic 
resistance, the pathogen has recently developed resistance to carbapenE!m 
antibiotics leaving limited treatment options and causing an increase in concern 
over the spread of carbapenemases expressing K. pneumoniae (KPC) st-ains 
which are associated with mortality rates of bacteremia ranging from 24% to 70% 
[15]. Current treatment options for KPC infections include the use of polymyxin 
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combination therapies (73% success rate) or tigecycline (71 % success rate) [12]. 
While K. pneumoniae nosocomial infections are primarily found in western 
countries, in developing countries community-acquired K. pneumoniae irfections 
are more prevalent [16-18]. 
1.2.2 Community-Acquired Infections 
In Southeast Asia and Africa, K. pneumoniae is among the most 
frequently isolated causative agents of community-acquired pneumonia (CAP) 
(15.8%). This geographical representation of CAP could be due to differe,nces in 
bacterial strains, host defense, or socioeconomic factors (e.g. environmental 
sanitation and primary healthcare) [19, 20]. In a worldwide study, 5% of patients 
in Taiwan and South Africa received antibiotic treatment prior to hospitalization 
compared to 23% of patients in westernized countries [19]. Additionally, '1/5 of 
patients admitted to hospitals with community-acquired K. pneumoniae 
presented bacteremia and required intensive care with mortality rates raiBing up 
to 55% [21-23]. K. pneumoniae CAP infections are associated with alcoh::>lism in 
South Africa and Taiwan as 18% of the patients were alcoholics unlike 
westernized countries where alcoholism is not prevalent in patients [19]. 
In Taiwan, the manifestation of soft tissue infection caused by community-
acquired K. pneumoniae was originally characterized as a liver abscess cmd the 
patients who were diagnosed with this disease had an overall mortality rate of 
23% [24, 25]. Liver abscesses associated with K. pneumoniae are associated 
with K1 or K2 serotypes and have been predominately found in Southeast Asia 
with the infections often complicated with meningitis, which results in a mortality 
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rate of 30% to 40% [24,26,27]. This prominence of K. pneumoniae in both 
nosocomial and community-acquired infections has highlighted the impo 1ance of 
identifying mechanisms of virulence for this pathogen. 
1.3 Virulence Factors: 
1.3.1 Siderophores 
Iron is a critical co-factor for K. pneumoniae virulence in animal models as 
it functions as a redox catalyst in proteins participating in oxygen and electron 
transport processes [28, 29]. K. pneumoniae secures iron from hosts by 
secreting siderophores such as yersiniabactin that competitively take up iron 
bound to host proteins [30-34]. More virulent strains of K. pneumoniae have been 
found to express three siderophores, yersiniabactin, enterobactin and 
salmochelin, suggesting that these three siderophores may playa key role in 
enhancing the virulence of the pathogen in an intranasal mouse model pO, 33, 
35]. 
1.3.2.1 Fimbrial Adhesion 
The ability of K. pneumoniae to adhere to mucosal and epithelial cell 
surfaces is mediated in part through fimbriae adhesions, a key componellt to 
colonization and infection [36]. K. pneumoniae possesses 2 types of fimbriae: i) 
Type 1 fimbriae which facilitates attachment to bladder epithelium [37, 3f1] and ii) 
Type 3 fimbriae which mediates biofilm formation in endothelial cells, as i/IIell as 
adhesion to the basement membrane of lung tilssue [39-41]. 
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1.3.2.2 Biofilm Formation 
Fimbriae are required for biofilm formation of K. pneumoniae and facilitate 
the colonization of various ecological niches [40]. Biofilm formation allow~i K. 
pneumoniae to colonize surfaces like catheters in hospitalized patients and has 
led to the spread of nosocomial infections [39]. The biofilm is linked to en 1anced 
bacterial resistance to antibiotic therapies and host defenses against K. 
pneumoniae [42, 43]. 
1.3.3 Lipopolysaccharide 
The lipopolysaccharide (LPS) of K. pneumoniae is a major component of 
the outer membrane which consists of lipid A, a core polysaccharide, and the 
side chain O-antigen polysaccharide. LPS is critical for K. pneumoniae to resist 
complement-mediated killing during infection [44]. The structure of the 
oligosaccharide-repeating units of the O-antigen of K. pneumoniae's LPS serves 
as a site for attachment of surfactant protein 0, which decreases the adhHsion to 
lung epithelial cells [45]. Surfactant protein 0 plays an important role in the 
regulation of innate immune responses in the lungs and causes agglutination and 
enhanced macrophage-dependent killing of K. pneumoniae [46]. Klebsiella 
strains that bind and agglutinate surfactant protein 0 by their mannose-rich 0 
antigens are less able to infect the lungs compared to strains expressing 
galactose-rich 0 antigens [47]. K. pneumoniae that expresses 0 antigen 
recognized by surfactant protein 0 triggers the induction of cytokine respclnse, 
which sets the stage for the innate immunity components [47]. The LPS of K. 
pneumoniae is considered to be a major virulence factor, which helps the 
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bacteria evade host immune responses and promote the persistence of illfection 
in various hosts. 
1.3.4 Capsular Polysaccharide 
The capsular polysaccharide (CPS) of /'(. pneumoniae covers the iJacterial 
surface and protects the bacterium from the host's inflammatory respons'3, from 
opsonization, and subsequent phagocytosis [48]. K. pneumoniae produces a 
large hydrophilic capsule (160nm) consists of repeating subunits of 4 to Ei sugars 
(glucose, galactose, mannose, fucose and rhamnose) with numerous 
configurations leading to a diverse capsule library of 80 different capsulal· 
antigens which has been described for Klebsiella [49]. 
1.3.4.1 CPS Regulation 
The mucoid phenotype found in liver abscess isolates is thought to be 
regulated by the rmpA gene [50]. The serotypes K1 and K2 are significantly more 
prevalent in strains that cause liver abscess than in the strains causing 
bacteremia alone [51]. In the K2 serotype strains, the rmpA has an isoforll 
rmp2A gene that has shown to regulate CPS biosynthesis [52]. The rmpA and 
rmp2A gene belongs to the UhpA-LuxR family of transcription factors, which also 
includes rcsA and rcsB that are also known as regulatory genes for capsule 
synthesis [53]. The RscA, RmpA or RmpA2 proteins have all been demonstrated 
to interact with the RcsB protein to form a heterodimer in order to bind 
specifically to the CPS promoter for transcription initiation [52, 54-56]. Th s 
regulation of the CPS by the RscA, RmpA or RmpA2 proteins has been 
demonstrated to be associated with temperature as the production of the CPS is 
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at maximum levels when bacterial growth rate is low [57]. Since the biosynthesis 
of capsule in K. pneumoniae is controlled by a two-component regulatory system 
[54, 58], it is likely that multiple accessory factors may be used in order t() 
increase the CPS biosynthesis in response to different environmental stimuli [52, 
55]. 
1.3.4.2 Complement Cascade Defense 
The CPS of K. pneumoniae resists the nonspecific host defense 
mechanism such as the complement cascade, which plays a crucial role in the 
early host defense against invading pathogens [59]. In vitro studies have shown 
that CPS inhibits the deposit of the C3 complement component onto the 
bacteria's surface and reduces the formation of the membrane attack corr'lplex 
[60,61]. K. pneumoniae strains that express low amounts of CPS can caJse an 
increase of complement activators which increases deposit of C3 and both 
complement-mediated and opsonophagocytic killing [60]. 
1.3.4.3 Antimicrobial Peptide Defense 
Antimicrobial peptides pose a threat to the survival of K. pneumon/ae 
during infection and the CPS acts as a countermeasure that can limit 
antimicrobial peptides interaction with the bactE~rial cell. The CPS mimics human 
cells by expressing polysialic acids in the capsule causing K. pneumoniao to be 
poorly immunogenic [62]. In vitro findings show that low concentrations of 
antimicrobial peptides (APs) up-regulate transcription of CPS, increasing the 
amount of capsule particulates shed by K. pneumoniae from its cell surfaGe [63]. 
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Additionally, free anionic CPS released from J( pneumoniae naturally at1racts AP 
neutralizing the killing ability of APs [64]. 
1.3.4.4 CPS Cluster Organization 
CPS gene clusters are found in a single chromosomal locus, which allows 
the coordinate regulation of a large number of genes involved in the biosynthesis 
and export of the CPS [65]. Sequenced Klebsiella strains have 8 genes (gaIF, 
acid PPC, wzi, wza, wzb, wzc, gnd and ugd) that are highly conserved in the 
CPS clusters [66]. The JUMPstart (for "just upstream of many polysaccharide 
starts") [67] element is part of transcriptional antitermination of the CPS cluster 
and is found upstream of the gene wzi. Genes wza, wzb and wzc are a common 
translocation-surface assembly pathway for cell surface CPS [66]. The mgions 
described above are called "Region 1" and encode for the proteins neceHsary for 
translocation of the polysaccharide through the peri plasm and across the outer 
membrane [68]. The region following these genes is serotype-specific and is 
responsible for biosynthesis and polymerization of oligosaccharide repeating 
units [68]. 
1.3.4.5 magA 
The magA gene is located in the CPS cluster of K. pneumoniae of K1 
serotype has been identified as a virulence gene, responsible for the 
hypermucoviscosity phenotype. The magA gene has been reported with a high 
prevalence of 98.1 % for K. pneumoniae isolates from patients with liver 
abscesses [50]. The disruption of the magA gene has resulted in the complete 
loss of resistance to serum and phagocytosis with greater than a 105-fold 
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increase in LDso for mice [69]. More recent studies, indicate that magA is a good 
tool for molecular typing rather than a major virulence determinant for K. 
pneumoniae strains that cause liver abscesses [50]. MagA and rmpA have been 
proposed as good markers for the rapid diagnosis of liver abscess [70,71]. 
1.4 Animal Models 
The use of animal models aids our understanding of the pathogeresis of 
infectious diseases, as well as, the development of therapeutics and vac:ines. 
Given that K. pneumoniae is capable of coloni;~ing a wide-range of host niches 
several surrogate animal models have been developed to study the path ::>genesis 
of this bacterium. In vivo experiments involving K. pneumoniae in the mouse 
model use a number of routes of infection: UTI, intramuscular, intravenous, 
intraperitoneal, oral inoculation, intranasal, surgical intratracheal and/or rlon-
surgical intratracheal infection [72-78]. In the mouse model, there are thn3e 
models that have been used to study pulmonary infection and they are: 
intranasal, surgical intratracheal and/or non-surgical intratracheal infecticn. All 
three models are designed to inoculate the lung to model human respiratory 
disease caused by both community-acquired pneumonia as well as nosocomial 
(e.g. ventilator associated pneumonia disease). The lung possesses several 
forms of innate defenses against invading organisms including physical barrier, 
the ciliary clearance of mucus from the lungs, and the rapid epithelial cell 
signaling of immunoprotection, such as the activation of resident alveolar 
macrophages [79]. 
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1.4.1 Intranasal Model 
The in vivo intranasal route of infection ~s used to target the lungs, which 
K. pneumoniae readily colonizes and is found to disseminates to both thH liver 
and the spleen following intranasal infection [7:2]. Infections established by 
intranasal delivery using strain ATCC 43816 resulted in rapid fatal disea~,e of 
mice with a mortality rate at 2 to 4 day and LDso values of 3.0 x 103 [72, BO]. 
Even though rapid morality occurs in the intranasal infection model, the lower 
respiratory tract is only one of three sites the inoculum is able to infect. VI/hen the 
inoculum is deposited in the nares, it is able to infect both the upper and lower 
respiratory track along with the digestive track [81]. Although K. pneumoniae is 
known to infect all of these three locations, the target organ when using the 
intranasal infection model is the lungs [81]. 
1.4.2 Surgical Intratracheal Model 
The benefit of the intratracheal model is the direct delivery of K. 
pneumoniae to the lungs and the avoidance of the infection in the upper 
respiratory track. The surgical method involves the an incision to the venl ral neck 
skin to expose the trachea, injecting the bacterial suspension by needle through 
the trachea, and then stitching up the incision [82]. The intratracheal infection 
using strain ATCC 4386 closely mimics intranasal infection rapid mortalit~' rate 
with similar LD50 values (2 x 103) in ICR strain mice [83]. However, this method is 
supposed to enhance delivery specifically to the lungs, but the trauma caused by 
surgery has the potential to initiate a secondary infection. 
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1.4.3 Non-surgical Intratracheal Model 
In our laboratory, we developed a non-surgical, intubation-mediated 
intratracheal model (IMIT) for K. pneumoniae respiratory disease studies. This 
method involves intubation of mice followed by injection of the inoculum ::Iirectly 
into the lungs [84]. The non-surgical intratracheal model removes infection from 
the upper respiratory track while also eliminating the trauma caused by tile 
surgical method and mimics contaminated ventilation catheters of hospihls in the 
US. This mode of infection ensures complete delivery of the inoculum to the 
lungs to simulate bacterial pneumonia in humans. We have identified an LOso of 
4.71 x 101 for K. pneumoniae ATCC 43816 by the IMIT model in BALB/c mice 
[84] and 103.6 CFU in female C57BU6 mice (unpublished findings). This [MIT 
model demonstrates a lung-specific infection model which mimics the 
contaminated ventilation catheters which is the major mode of infection for 
hospitals acquired K. pneumoniae pneumonia infections in the US. 
1.5 Hypothesis 
Capsule is an important virulence determinant for K. pneumoniae, 
however, recent Next Generation Sequencing efforts conducted by our laboratory 
failed to fully sequence the K2 CPS cluster from strain ATCC 43816, a commonly 
used K. pneumoniae strain to study respiratory disease. We predicted that K2 
CPS clusters would be highly conserved with previously sequenced K2 CPS 
clusters, and that the sequence of the ATCC 43816 K2 CPS cluster would allow 
us to preform subsequent studies to investigate the role of CPS in K. 
pneumoniae virulence. We also aimed to deve~op a novel bioluminescen·: strain 
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of K. pneumoniae through stable chromosomal introduction of the lux op~ron, 
allowing for the monitoring of the disease process in cell infection assay~. and 
living animals. Finally, combining the use of these new tools (CPS seque nce and 
bioluminescent K. pneumonia e) , we intended to monitor the role of K. 
pneumoniae CPS in in vivo studies. 
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CHAPTER II 
MATERIALS AND METHODS 
2.1 Bacterial Strains and Media 
All bacteria were stored in -80°C as 25% glycerol stocks and cultllred in 
Luria broth (LB; Lennox, 1955) overnight at 3rC with shaking at 200 rpr1 unless 
otherwise stated. All Klebsiella strains were thl3n subcultured (1 :25, vol/vol) into 
2.5 ml trypticase soy broth (dialyzed and chelated) (TSBDC; Brett et aI., 1997) 
containing fresh monosodium glutamate (2.5 M MSG stock) at a 1 :50 
concentration and grown at 3rC for 3 hours unless otherwise noted. E. ';oli 
strain DH10B was used for cloning and E. coli strain S17-1 was used for 
conjugation with K. pneumoniae. When appropriate, antibiotics were used at the 
following concentrations: kanamycin (Km: 25 IJg/ml) , gentamicin (Gm: 2C !-Ig/ml 
for NTUH and ATCC, 1000 !-Ig/ml for MGH), carbenicillin (Cb: 100 !-Ig/ml) , and 
zeocin (leo: 25 !-Ig/ml or 100 !-Ig/ml). Details of strains and plasm ids used in this 
study are shown in Table 2.1. 
2.2 Molecular Biology 
2.2.1 PCR Reactions 
PCR amplification of cloning fragments or for PCR sequencing of fragments 
smaller than 4 Kb was performed with Phusion High-Fidelity DNA polymerase 
using the following protocol: initial denaturation at 98°C for 30 seconds followed 
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Table 2.1 
Bacterial Strains and Vectors 
Strain Genotype/descri~tion Source 
DH10B 
Electrocompetent E. coli cloning 
Invitrogen 
strain 
S17-1 A pir E. coli strain for conjugation [85] 
ATCC 43816 K. pneumoniae [86] 
NTUH-K2044 K. pneumoniae [9] 
MGH 78578 K. pneumoniae [72] 
ATCC43816::pJM 
K. pneumoniae::pJMW106-gaIF This Study 
W106 -galF 
ATCC43816::pJM 







K. pneumoniae:: Kp A TCC-nif-
This Study PrplU-lux 
Plasmid 
pJET1.2 Blunt cloning vector Fermentas 
pCR4 




TOPO-TA Cloning vector harboring 
This Study galF fragment 
pCR4-uge 












Table 2.1 continued 
Bacterial Strains and Vectors 
Plasmid 
pSK pBluescript SK (+) Stratagene 
pSK-~cap-leo 




pBluescript SK (+) vector 
This Study 
harboring ~cap 




Suicide vector harboring ~cap-
This Study 
leo 
pJMW1 06-~cap Suicide vector harboring ~cap This Study 
pGSVS Suicide vector This Study 
pKSVS2 Suicide vector This Stud'y 
pKSVS2-Kp ATCC-nit- Suicide vector harboring PrplU-
This Study 
PrpIU-lux-floxleo lux-floxleo 
pKSVS2-Kp ATCC-nit- Suicide vector harboring PrpIU-
This Stud'( PrplU-lux lux 
pKSVS-ptoIC-ere 
Suicide vector harboring PtolC-
This Stud:( ere 
pKSVS-PtoIC-cre-gaIF 
Suicide vector harboring PtolC-
This Stud:( ere-galF 
15 
by 30 cycles based on the following: 98°C for 10 seconds, 68°C for 30 sE'conds 
and 72°C for 60 seconds for 1-2 Kb fragment, '120 seconds for 2-4 Kb fragments 
and the final extension of fragment at 72°C for 10 minutes. Long Range PCR 
amplification was performed with Phusion High-Fidelity DNA polymerase for 
fragments larger than 4 Kb. The following protocol is used for long-range PCRs: 
initial denaturation at 98°C for 30 seconds followed by 30 cycles based 01 the 
following: 98°C for 10 seconds, 68°C for 30 seeonds and 72°C for 300 sEconds 
for 4-8 Kb fragment or 600 seconds for 20 Kb fragments, and the final ex:ension 
of fragment at 72°C for 10 minutes. All primers used are listed in Table 2.2. 
2.2.2 Bacterial Enumerations 
Viable cell count was performed by serial dilution of the original sample in 
PBS, plating aliquots of the dilutions in triplicatE~ onto an LB plates and thl~n 
incubating at 37° for 8 hours or at room temperature for 24 hours. After 
incubation, the colonies were enumerated and the number of viable cells was 
calculated. Serial dilution was conducted in a 96 well plate using 6 fold sE!rial 
dilutions in eight wells. A multichannel pipettor was subsequently used to replica 
plate the samples on an LB agar plate for enumeration (Figure 2.1). 
2.3 Sequencing Capsular Polysaccharide Cluster 
Next Generation Sequencing (NGS) was performed on ATCC 43S 16 
which yielded five contigs of DNA spanning the capsule cluster. The five contigs 
were bridged using either genomic DNA captune or primer walking techniques. 
Similar methods were used in order to close gaps in contig level sequenc ng 




Primer Oligonucleotide Sequence (5' -~ 3') Number 
1 galF Sacl (+) GCGAGCTCCAGGCGCAGCCGCTGGG(;CTGG GCCACTC 
2 galF Xbal (-) GTTCTAGACCGGCCCAGATATCCGCCGACAG CACGTAG 
3 uge Sacl (+) GCGAGCTCCGGGCTGCGCTTCTTTACAGTGT ATGGTCCGTG 
4 uge Xbal (-) GCTCTAGAGTCCAGCACATCTCCCGGCTGGA TCGGCATCATATTCTTCTG 
5 43816cap8-1 (+) GCTTCCAGCTCGTAGGAGGTGTCGAAGTGG 
6 43816cap8-2 (-) ACAGCAT AA n-AAA TCGCGGGCGCT AAAGCTG AAGTCG 
7 43816cap4-1 (+) GTGATGGTTTCCTGTAGCATGGAGTTCTGCCC G 
8 43816cap4-2 (-) CAGTTCCTGCAAAAGATCACTGATGCTfATGC GCAAAACG 
9 43816cap3-1 (-) TGGATCCGCGTATCGGCAACCATTATAACAAC CCG 
10 43816cap3-2 (+) GCGGGTGTAAACCTTGTCCGCCACATCTGC 
11 43816cap3-3 (-) GGAATGGAAGCGCAGAAGAATATGATGCC 
12 43816cap3-4 (+) GTTCTTCAACTCCCGCGTCGTGCG 
13 43816cap5-1 (+) CTTCAGCAATCAGCTGCATGTCACCATACTCA ATGCC 
14 43816cap7-2 (-) ATGCTGATGACCGGCGAAAGCTACGACTGCG 
15 43816wzi (+) CCAACGTCATCGCTGTCGCTGTTGTTA3CG 
16 43816wzi (-) TCGACATGGCCGCTAAGCCAGGAAGAGATCG 
17 43816 wzc (+) GCGACAA TACACCTGTATCTTTTCCAG--ATCT GCGACAG 
18 43816 wzc (-) TA TT AA TGGGGAGTCGCA TTGAAAAGTfCCTT GAGTGGGC 
19 43816cap7-3 (+) GTACAACTGGGCTGGAGCGGTGACG 
20 43816cap7-4 (+) ATCACCCGGAGCTGACAACACCTGC 
21 43816cap7-5 (+) GGCAATGCTGAAGGTATGTCGCAAGCG 
22 43816cap7-6 (+) CAACATTGCACCCGAAGCACGAGG 
23 43816cap7-7 (+) GGGCAAGGTT,AAGTGGAGAGCACCAG I3G 
24 43816cap7-8 (-) GAGTCTCAGGCATTGTTGCAACACGC 
25 43816cap7 -9 (-) GCAAGATCCGCAGGATTTTCTGTAGCAAGTAA 
26 galF-wzi (+) AAAGAAGGCGCCAAA TTCCGCGAAAGTA TT AA AAAACTGC 
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Table 2.2 continued 
Oligonucleotides 
Primer Oligonucleotide Sequence (5' -~ 3') 
Number 
27 43816wza-wzc( +) CAGCGACGCTACCGCCCCTGGC 
28 wzi-wzc (+) GTGTCTGACCAAACCCCTGCGGAGTGC 
29 43816wzi-wza (+) CGCGTA TI ACACCAGCGCCTGTCTGC C 
30 43816wzi2 (-) CGTCATCGCTGTCGCTGTIGTIAGC 
31 Chedid ort 9 (+) GTTICAACTGATIGCCCATATCCTGCC 
32 Chedid ort 9 (-) GCAAATAGCACTICGTCATIGG 
33 CTATCTCGTATTCTGGAGCCATTIGAATTCGG 43816wzx (+) TGTITIGTC 
34 43816wzx (-) GACGAAA TAAGCCTTICATCTCAGCNl.GT AAC TIATIAGGGC 
35 43816Cap6-3 (+) ACTATGAGTATAAATGTGCTGTAGATGCAGG 
36 43816Cap6-4 (+) CATCTAATAN~TICAGGAAAAGCGATATGG 
37 43816Cap6-5 (+) CGA TIGCGGTATCA TI ATGGTCGC 
38 43816cap5-3 (-) GTGGTCACTGCGACACGTICGCAGC 
39 43816cap5-4 (-) GCGCAAGGTIACGCCCCATCACAGCC 
40 43816cap5-5 (-) CGGACATCTGACCAAAAAGTACGTI NAGAA CTGCGG 
41 43816cap5-6 (-) CCTCAAACCCTAACCAAGGCTGC 
42 43816cap5-7 (-) GGAAGCATTIGCATICGAGCG 
43 43816cap5-8 (-) CGTGATIAACATTIGACAACCCG 
44 43816cap5-9 (-) CGCGCCTGGAGTGAAACACCATC 
45 43816cap5-10 (-) CAGTATAACTCCGATIATCAGCAAAC 
46 43816cap5-11 (-) GAGGTAAGCATICGTIGTGTGCCGC 
47 43816cap5-12 (-) GCTICTIGGCCACTAATAAAAACACACTCACC 
48 43816cap5-13 (+) CGCTCGGTATTGCTGGCCATGAGGC 
49 43816cap5-14 (+) CGTIAGTACAAGCATIGGAAGTGAGGGCACT GGAAC 
50 43816cap5-15 (-) GACAAAACACCGAATICAAATGGCTCCAG 
51 43816cap5-16 (-) CCCCTTGTTGCCACGGATGAATATGTGTCTAT ATCACTTGCAAGTGC 
52 galF EcoRI (+) GAGAA TICGTGAAAAACAA TCAGCGG1TTGG TCAGGGTG 
53 galf Xhol (-) ATCTCGAGTCCTGCGACCGGAATAACCGC 
54 ugd Xhol (+) CCCTCGAGCTGTTIGGTAACGATIAATTCTGC CTG 
55 ugd Kpnl (-) ACGGTACCGCTGTATGACCTGGTGGG C 
56 5' Kpin2 EcoRI(+) GAAGAA TTCCGCGCCGGGACGGTCCATCTIG TTGACGAAGGCCAGCC 
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Table 2.2 continued 
Oligonucleotides 
Primer Oligonucleotide Sequence (5' ~ 3') 
Number 
57 
5' Kpin2 Nhel(-) CAGCAGCGTATCCAGCAGGCCGGGAA~CGG 
int1 GCGTCCAGGTCTTCCCG 
58 
3' Kpin2 Kpnl(-) GTCGGTACCGTGA TTT ATGGCGTGTTTGAAGG 
new CGAGGG 
59 
3' Kpin2 Nhel(+) GCGGCTAGCCCTGACCCGGCCTACGG~GGC 
new2 CGCCCGTCAGCTTATGTCC 
60 floxZeo BspEI(+) 
CTTCCGGATGGCTCGAGTTTTTCAGCAAGATG 
TCCGGATCATAACTTCG 






Plating Scheme for Bacterial Enumerations 
To enumerate bacteria, samples were diluted through serial dilutions on a 96 well 
plate, and a row of eight samples was replica plated in 10 IJI aliquots on an LB 




NTUH-K2044 (AN: AB198423), and MGH 78578 (AN: CP000647). 
2.3.1 Genomic Capture 
The genomic capture process was performed by using insertional 
mutagenesis to insert the vector pJMW106 into the gafF and uge genes located 
in or near the capsule cluster. Approximately 400 bp fragments containir g 
portions of the genes gafF and uge were PCR amplified using primer pairs 1/2 
and 3/4 (Table 2.2). Each fragment was cloned into pCR4 vector generating the 
vectors pCR4-ga/f and pCR4-uge respectively. The gafF and uge fragmE!nts were 
then cloned into the pJMW106 vector using the Sacl/Xbal restriction sites to 
generate the plasmids pJMW106-gafF and pJMW106-uge respectively. 817-1 
was used to conjugate the pJMW1 06-gafF and pJMW1 06-uge construct~, into K. 
pneumoniae ATCC 43816 and integration of the constructs were selecte j on 
carbenicillin and kanamycin LB plates. Insertions were confirmed by pcn and 
named ATCC43816::pJMW106-gafF and ATCC43816::pJMW106-uge, 
respectively. 
ATCC43816::pJMW106-gafF and ATCC43816::pJMW106-uge genomic 
DNA was isolated using the Promega Wizard Genomic DNA purification Kit. 
Genomic DNA was digested using one of the following enzymes: EcoRI, Spel, 
Notl or Sac!. The digested genomic DNA was then ligated and electroporated 
into DH 1 OB and grown on Km25 plates. Single colonies were chosen and grown 
in LB broth containing kanamycin at 3rC with shaking. Plasmid DNA was 
isolated by miniprep and digested using an appropriate restriction enzyme (listed 
above). The digestion mixture was then placed into agarose gel for gel 
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electrophoresis to show fragment captured along with the pJMW106 vector. 
Sequencing efforts were conducted to characterize the captured chrome somal 
fragments. 
2.3.2 Primer Walking 
PCR was used to close gaps between contigs that were missing from the 
NGS of ATCC 43816 genome. Long range PCR was used to acquire template to 
be used for primer walking. The first step was to extend the boundary of known 
sequence into the unknown region of template by using PCR base primer 
extension. Primers were then designed based off of the newly acquired 
sequence and used to extend boundary of known sequence into unknown region 
in an iterative process. All oligonucleotides used are listed in Table 2. 
2.3.3 Sequencing of CPS Cluster 
NGS returned five contigs of DNA spanning the capsule cluster IElaving 4 
gaps to close. Using ATCC 43816 genomic DNA, a 1.2 Kb fragment was PCR 
amplified and sequenced using primer pair 5/6 (Table 2.2 and Figure 2.2) to 
sequence the gap adjacent to gene gafF. Subsequently, a 673-bp fragment was 
PCR amplified and sequenced using primer pair 7/8 (Table 2.2 and Figure 2.2) to 
sequence the gap between genes gnd and manG. A 1.5-Kb fragment was PCR 
amplified using primer pair 9/10 (Table 2.2 and Figure 2.2) for template to 
sequence the region from genes ugd to uge. Primers 9, 10, 11, and 12 (Table 2.2 
and Figure 2.2) were used to sequence the 1.5-Kb fragment connecting 
sequence of genes ugd and uge. 
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Using long range PCR, a 20-Kb fragment was amplified using the primer 
pair 13/14 (Table 2.2 and Figure 2.2). This 20-Kb fragment was used for template 
to sequence remaining region between genes gafF and gnd. Primers were 
designed based off Chedid and NTUH-K2044 sequence and the following two 
primer pairs 15/16 and 17/18 (Table 2.2 and Figure 2.2) were used to acquire 
two sequencing islands at 5' end of CPS cluster. This gave us two sequEmcing 
gaps between genes gafF and wzc and using the primer walking technique made 
use of primers 19-30 to complete closing of the gap (Table 2.2 and Figure 2.2). 
Primers were designed based off Chedid sequence, and the two primer 
pairs 31/32 and 33/34 (Table 2.2 and Figure 2.2) were used to acquire two 
sequencing islands in the central region of the CPS cluster. The remaining 
sequence was acquired using the primer walking technique primers 35-51 (Table 
2.2 and Figure 2.2). The sequence was then manually aligned in Microsoft 2010 
Word. 
2.4 CPS Cluster Annotations 
The sequenced capsule cluster was analyzed using Acaclone pDraw32 
DNA analysis software to predict open reading frames (ORFs) encoding for 
putative proteins greater than 35 amino acids. Homology searches of pu1ative 
proteins predicted by pDraw32 were conducted using BLASTP Genbank (NCBI) 
database. The gene name, description, and probable function of each pmdicted 
gene was assigned according to the results of BLASTP (identity 70% and results 
of BLASTP (identity 70% and matched length 80%) against NCBI K. pne,lmoniae 
















homology of putative proteins identified by pOraw32 to all published K. 
pneumoniae sequenced CPS clusters as of 12/1/12. The K. pneumoniae strains 
used with accession number (AN) were: serotype K1 (NTUH-K2044 AN: 
AP006725 and OTS AN: AY762939), K2 (CHEOIO AN: 021242 and VGI-I-535 
AN: AB371296), K5 (NTUH-K9534 AN: AB289646 and VGH404 AN: AB371292), 
K9 (VGH484 AN: AB371293), K14 (VGH916 AN: 371294), K20 (NTUH-KP13 
AN: AB289648 and 889/50 AN: AB289647), K52 (MGH 78578 AN: CPO(0647), 
K54 (NTUH-KP35 AN: AB289650) K57 (A1142 AN: AB334776), K62 (VGH698 
AN: AB371295), non-typeable (NT) strain (A1517 AN: AB334777) and not 
determined (NO) serotypes (NK29 AN: AB371290, NK8 AN: AB371289, NK245 
AN: AB371291, KCTC 2242 AN: CP002910, HS11286 AN: CP003200, ~~p13 AN: 
377737, and 1084 AN: CP003785). 
2.5 Mutagenesis and Construction of the K. pneumoniae Capsule CI uster 
Acap Mutant 
Allelic exchange mutagenesis was performed in K. pneumoniae A TCC 
43816 using the vector pJMW1 06. 1-Kb fragment containing a portion of the 
gene gafF was PCR amplified using the primer pair 52/53 (Table 2.2) to make a 
1-Kb fragment containing a portion of the gene a ugd was PCR amplified using 
primer pair 54/55 (Table 2.2). The two fragments were cloned separately into 
pJET1.2 and the two PCR fragments were then subsequently assembled 
together using the common Xhol restriction site into the pSK vector creating the 
vector pSK-~cap. A 500-bp fragment containing the zeocin antibiotic marker Sh 
bfe gene was PCR amplified using primer pairs 60/61 (Table 2.2).The fra~ment 
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was cloned into the common Xhol site between fragments gafF and ugd in the 
vector pSK-Lkap creating vector pSK Llcap-Zeo. The assembled 2.5-Kb dcap-
Zeo fragment was cloned into pJMW106 using EcoRl/Kpnl restrictions sites to 
generate the allelic exchange plasmid pJMW106-dcap-Zeo. S17-1 was lIsed to 
conjugate the pJMW106-dcap-Zeo construct into K. pneumoniae ATCC 43816 
for the two-stage allelic exchange procedure, with the first stage selectin'~ for 
integration of the construct on LB agar plates containing carbenicillin and 
kanamycin to isolate a merodiploid colonies. Single colonies were chosen and 
grown in LB broth containing carbenicillin, kanamycin and zeocin. The second 
stage of the allelic exchange procedure was done to select for the excision of the 
vector from the genome while also removing the CPS cluster. 20 1-11 of LB broth 
containing merodiploid colony grown in carbenicillin, kanamycin and zeoGin was 
transferred to LB broth contain 15% sucrose and grown at room temperature 
overnight. Subsequently, the next day 10 1-11 of LB broth was transferred to LB 
agar plates containing 15% sucrose and grown at room temperature ovemight. 
The following day single colonies were transferred to a LB agar plate containing 
kanamycin followed by the transformation to an LB agar plate to confirm ':he loss 
of the vector and the 25,000-bp fragment. 
2.6 Infection of Cultured Macrophages 
J774A.1 cells were maintained in DMEM (Gibco 11995) medium 
supplemented with 10% heat-inactivated fetal bovine serum (HyClone) and 
grown at 37°C with 5% CO2 and 100% humidity. For infection studies, 
monolayers of J774A.1 cells were seeded at a concentration of 7.5x104 cells per 
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well (100 IJI) in a white 96-well plate (Greiner Bio-One) one day prior to illfection. 
K. pneumoniae strains were grown as described above and bacterial 
concentrations were estimated using spectrophotometry. The bacterial 
suspensions were diluted in PBS to reach an MOl of 10,3 and 1 and 5 j.J1 aliquot 
was inoculated into each well containing J774A.1 cells. One hour post-
inoculation, gentamicin was added to each well to kill the extracellular bctCteria. 
At 3,4.5,6,9 and 12 hour post-inoculation, OM EM media was removed and 100 
IJI of 0.1 % Trition was added to lyse cells. The solution was then transferred to 96 
well U-bottom plate for bacterial enumeration (2.2.2). 
2.7 Chromosomal Introduction of /uxCDABE Operon 
We designed lux knock-in mutation using allelic exchange strategy to 
insert the lux operon between genes fusA and yeeF. A 407 -bp fragment lNas 
synthesized containing the stem loop terminator from the K. pneumoniae 
genome and the promoter gene PrplUto regulate lux production. The two PCR 
fragments from the K. pneumoniae genome [primer pair 57/58 (Table 2.2) and 
59/60] were cloned separately into pSK at EcoRIIApal (1192-bp) and No·:IIKpnl 
(1074-bp) fragments (Figure 2.3). The synthesized fragment was assembled 
together with 5' fragment using the common BsiWI site engineered into both the 
promoter and the 5' fragments were added to the pSK 5' Kpin2 vector. Tile two 
fragments (5' Kpin2-PrplU and 3' Kpin2) were then assembled in pGSVS on 
either end of the lux operon to yield pGSVS-Kpin-PrpIU-lux (Figure 2.3). 
The zeocin antibiotic marker Sh ble gene was PCR amplified usin!~ 
primers 60/61. The fragment was cloned into pSK creating the vector pSI< 
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floxZeo. The floxZeo fragment was then cloned between 3' fragment and luxC 
gene of the lux operon in the plasmid pGSVS-Kpin-PrpIU-lux. This created the 
plasmid called pGSVS2-Kp ATCC-PrpIU-lux-floxZeo (Figure 2.3). The as:)embled 
pGSVS2-Kp ATCC-PrpIU-lux-floxZeo plasmid was electroporated into S17-1 and 
then conjugated into K. pneumoniae ATCC 43816 for a two-stage allelic 
exchange procedure described above. The ATCC 43816::Kp ATCC-PrpIU-lux-
floxZeo strain was named WKP001 (Figure 2.3). 
2.8 Removal of Zeocin Antibiotic Marker from Strain WKP001 
A 1-Kb fragment containing a portion of the gene galF was PCR amplified 
using primer pairs 1/2 and inserted into pSK creating pSK-galF. The 1-Kb 
fragment was then cloned into pKSVS-PtoIC-cre at Spel/Notl sites resulting in 
the vector pKSVS-PtoIC-cre-galF. Strain WKP001 and S17-1 pKSVS-PtoIC-cre-
galF were grown separately in 4 ml of LB broth shaken overnight at 37°C. On the 
following day, 1 ml of S17-1 pKSVS-PtoIC-cre-gaIFwas centrifuged for 1 minute 
at 15,000g. The pellet was washed with 10 mM MgS04 and centrifuged a,~ain. 
The pellet was re-suspended in 100 IJL ofWKP001 LB overnight culture clnd then 
transferred to a LB plate and grown at 3rC. Bacterial conjugation mixture was 
streaked for single colony isolation on a Cb100/Km25 LB plate and grown at 
3rC. Three single colonies were cultured overnight in 5 ml of LB broth with 15% 
sucrose at 3rC with shaking. Subsequently, 10 IJI of the overnight culturE! was 
streaked for single colonies on an LB plate and cultured at 3rC. The ten 
colonies were replica plated on both Km25 and Cb100 LB plates. Colonie) which 
were CbR/Kms were confirmed to be 
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Figure 2.3 
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also leos in LB le0100 broth and the strain was named JSKP001 (Figu'e 2.3). 
2.9 Investigation of the Light Production by Strain JSKP001 
K. pneumoniae strain JSKP001 was grown overnight in LB in triplicate and 
the cultures were subcultured in TSBDC broth in the 37°C incubator. Every 30 
minutes for 4 hours, 100 IJI was taken from each triplicate and bioluminescent 
measurements of plate were taken with Synergy HT plate reader (BioTel<, 
Winooski, VT) (1 sec read, sensitivity of 135). Additionally, at each 30 minute 
time point, 100 IJI was taken from each subculture processed for bacterial 
enumerations as described above. 
2.10 Chloramphenicol Spike of Strain JSKP001 
Sub-lethal concentrations of chloramphenicol (150 IJg/ml ) were added 1 
hour post-subculture to restrict new protein synthesis and subsequently restrict 
bacterial growth. Chloramphenicol was added at a final concentration of 150 
IJg/ml to JSKP001 cultures. Bacterial growth, bioluminescent measuremEmts, and 
enumerations were performed as described above. 
2.11 Infection of Cultured Cells with Bioluminescent Strain JSKPOO'I 
J774A.1 cells were infected in a black 96-well plate using strain JSKP001 
at an MOl of 10 to determine the correlation between bioluminescent readings 
and bacterial numbers of K. pneumoniae. The luminescent measurements 
(counts per second, cps) were taken with Synergy HT plate reader (BioTek, 
Winooski, VT) immediately before harvesting samples for bacterial enumerations 
at the 3, 4.5, 6, 9 and 12 hour post-infection time point, then immediately 
bacterial enumeration was conducted as described above. 
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2.12 Data Presentation and Statistical Analysis 
Unless otherwise stated, Graph Pad Prism 5 was used to plot data and 




GENOMIC ORGANIZATION OF K2 SEROTYPE K. PNEUMONIAE CPS 
3.1 Introduction 
K. pneumoniae ATCC 43816 is a representative K2 capsular serotype 
strain that has been shown to be virulent in murine respiratory disease models. 
Despite its relevance in the pathogenesis of respiratory disease, the genomic 
sequence had not been previously determined. Therefore, our laboratory 
performed Next Generation Sequencing (NGS) to acquire the sequence for the 
complete genome of the ATCC 43816 strain. The NGS gave us an estimated 
-80% coverage at the contig level based on previously sequenced genoilles of 
other K. pneumoniae stains [84]. This coverage is comparable to other NGS 
sequencing efforts [87, 88] and other historically used methods such as the 
shotgun approach and genome fragmentation [9, 89]. However, only 22.-12% 
sequence coverage of the CPS cluster was obtained from our NGS sequencing 
efforts. Given this underrepresentation and the importance of the CPS cllJster for 
virulence, we decided to manually sequence and assemble the remaindE!r of the 
cluster. This type of gap closure is historically done by assembling contigs using 
a large-insert library to determine orientation of contigs [9, 89], however, more 
recently orientation is based on homology to previously sequenced strains and 
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gaps are closed by sequencing PCR products [87, 88]. We used genom c 
capture, primer walking and long-range PCR to close the gaps in the sequence 
of the CPS cluster. 
3.2 Genomic Capture 
One approach we used to sequence the capsular polysaccharide cluster 
was the genomic capture technique by using insertional mutagenesis of the 
vectors pJMW106-gafF and pJMW106-uge, which flanked the CPS cluster 
returned by NGS (Figure 3.1, yellow bars). Homologous portions of gafF and uge 
genes were independently cloned into pJMW106, which is a non-replicating 
vector in K. pneumoniae. The vectors were named pJMW106-gafF and 
pJMW106-uge respectively and were conjugated into K. pneumoniae genome. 
Growth in LB broth containing kanamycin was used to select for insertion of the 
vector and the strains were named Kp ATCC::pJMW106-gafF and Kp 
ATCC::pJMW106-uge. Purified genomic DNA of Kp ATCC::pJMW106-gcrfF and 
Kp ATCC::pJMW106-uge was digested using a selection of enzymes available 
that would retain the vector backbone and capture out a large portion of the 
genomic DNA of the capsule cluster which was then ligated and amplified in E. 
coli S17-1. Initial efforts did result in capture of genomic DNA, however, other 
efforts described below yielded sequence more rapidly and, this technique was 
discontinued. 
3.3 Primer Walking and Long Range PCR 
We used primer walking and long range PCR to sequence the remaining 
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Schematic Diagram of Sequencing Efforts of CPS the ATCC 43816 Cluster 
Scale representation of the CPS cluster illustrating the progression of closing sequencing gaps using genomic 
capture and primer walking. The conserved CPS cluster (gafF to ugd) with gene identifiers indicated above each 
open reading frame represented by blue arrows. Missing gaps named (1 , 2, 3, 4 and 5) in ascending order of the 
direction of the ORFs. Row 1 (green bars) - contig level of NGS coverage; Row 2 (yellow bars) - sites for genomic 
capture by insertional mutants; Row 3 (orange bars) - closure of gaps 1,4 and 5; Row 4 (Red bars) - sequence 
obtained for genes wzi and wzc; Row 5 (blue bars) - finishing gaps 2; Row 6 (purple bars) - generating intermediate 
islands with genes wzx and ORF 9; Row 7 (teal bars) - gap 3 completed; Row 8, summary of gap closure efforts to 
sequence the CPS cluster. 
CPS cluster (Figure 3.1, green bars) and the remaining unsequenced re!~ion was 
broken up into five gaps. The small gaps 1, 4 and 5 were amplified by peR and 
sequenced using genomic DNA, leaving one large gap located between genes 
gafF and gnd (Figure 3.1, orange bars). Using long range PCR, a 20-Kb fragment 
was amplified and served as the template for sequencing the remaining region of 
the CPS cluster. Next, the sequence for the genes wzi and wze was obtclined 
using primer walking technique with the 20-Kb fragment as template (Figure 3.1, 
red bars) and provided two intermediate sequencing islands to extend th~ 
sequence from the gafF gene. A 7 -Kb gafF-wze fragment was amplified by PCR 
and this fragment was used as a template to close the gaps in sequence 
between gafF and wze (Figure 3.1, dark blue bar). The sequence from ORF 9 to 
wzx was determined by using previously sequence K2 serotype K. pneumoniae 
strains (Figure 3.1, pink bars) which providing two intermediate sequencing 
islands to connect the sequence of genes wze to gnd (Figure 3.1, teal bar). This 
completed the sequencing of the CPS cluster for the K2 serotype K. pnellmoniae 
strain ATCC 43816. 
3.4 GC content of K. pneumoniae ATCC 43816 K2 CPS cluster 
We investigated the GC content of the CPS cluster of K. pneumoniae ATCC 
43816 as this provides insight into the acquisition of the CPS cluster. ThE! CPS 
gene cluster of ATCC 43816 is 23,804 bp in length and contains 18 open reading 
frames (ORFs) from gafF to ugd (Figure 3.2). The average GC content of the 
capsular polysaccharide cluster is 42.02%. Interestingly, we observed a central 
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Organization of CPS Cluster for K. pneumoniae ATCC 43816 
The CPS spans from gafF to ugd and the open reading frames are represented by arrows. A plot of the GC content 
for the region using 30-bp sliding window is shown below the open reading frames. The red horizontal line represents 
the mean GC content (59.53%) of the Next Generation Sequencing which covered -80% of the genome. 
100 
GC content of 31.8% (Figure 3.2 and Table 3.1). By comparison, both the 
average CPS cluster and central region are well below the average GC content 
of the entire ATCC 43816 genome (59.5%)[84]. This observation of low GC 
content in the central region is consistent with 14 other K. pneumoniae CPS 
serotype clusters [90]. This suggests that there is a recent acquisition of the 
capsule cluster and perhaps rapid substitution of the core genetic element, which 
may impact plasticity of capsular serotype. 
3.5 Identification of K2-specific genes 
We analyzed the sequence of the K2 CPS cluster of K. pneumoniae strain 
ATCC 43816 against 23 other sequenced strains to identify the genes conserved 
between the K2 serotype (Figure 3.3). The open reading frames (ORFs) of ATCC 
43816 were annotated and given a probable function based on their alignment to 
previously sequenced K. pneumoniae strains (Table 3.1). When additional 
flanking sequence is available for sequenced K. pneumoniae CPS cluste rs, the 
cluster is always located between genes yegH and uge. At the 5' end of the CPS 
cluster there are six genes (gafF, acid PPC, wzi, wza, wzb and wzc) that are well 
conserved among all K. pneumoniae strains and have been described aH a 
common translocation-surface assembly pathway for cell surface CPS [66]. A 
central region located between genes wzc and gnd appears to be the variable 
region for the CPS clusters; however, a high homology is observed betwHen K. 
pneumoniae strains containing the same serotypes suggesting the variable 
region contains serotype specific genes (Figure 3.3). Amongst the sequenced K2 
isolates (n=3), we observed high homology at both the genetic and amino acid 
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Table 3.1 
General Features of the 18 Genes Identified in ATCC 43816 CPS Gene Cluster 
I I I I I I I , 
Kp (NTUH-K2044, K2, 
O-ea lactase syn~sis ealF 
UTP-eIUC02-1-phosphate 
ea lF 59.1 298 100% 
NTUH- 9534, K9, K14, 
uridy ran~rase K52, K62, NK245,Nk29, 
1084) 
Membrane-associBted lipid 
Ac idpPC Acid phosphate homoq AcldPPC 58.6 209 99% Kp(K2) 
phosphatase 
Polymerization and surface 
wzl Outer membrane protein wzi 54.2 477 99% Kp(K2) assembly 
Polymerization and surface 
wza 
Mult imeric putative 
\vza 43,8 378 96% Kp (K2, (CTC 2242) assembly transkxation channel 
Polymerization and surface 
wzb 
Protein tyrosine 
wzb 36.3 144 97% Kp (K2, CTC 2242) 
assembly phosphatase 
Polymerization and surface 
wzc 
Inner membrane tyrosine 
wzc 35.6 686 97% Kp (K2, ( CTC 2242) 
assembly autokinase 
Cata lV2ll! the transfer of suear ori7 
Group lelycosyl 
o rf7 30.9 358 99% Kp (K2, KCTC 2242) 
transferase 
Cata lV2ll!the transfer of suear ori8 
Group le1ycosyl 
ori8 30.7 400 100% Kp (K2, KCTC 2242) transferase 
Cata lV2ll!the transfer of suear orf9 
Group le1ycosyl 
orf9 30.1 286 96% Kp(K2) 
transferase 
Unknown oril0 Hypotheti ca protein orfl0 31.1 438 100% I<p (1<2, I<CTC 2242) 
Polymer ationand surface wzx Putative flippase w v( W V( 31,9 485 99% I<p (1<2) 
assembly 
Unknown orf 12 Hypothetical protein ori12 33.6 579 99% I<p (1<2, KCT(2242) 
Unknown ori13 Acetyl transferase ori 13 33,2 192 98% I<p (1<2, I<CTC 2242) 
UOP-elucase l ipid carrier 
Undecapn!ny~phosphate 




Kp (1<1, K5, K9, K14, 1<54, 
Unknown end end 49.8 333 91% K62, 1<C"C2242, NI<29, 
dehydroeenase 
1084) 
Synthesis of GOP-mannase 
manC 
GOP-mannase 
manC 61.4 471 100% I<p (1<1, 1084) from mannose-&phosphate phosphorylase 
Synthesis of mamose-l-
Kp(NTU~-K204~I<CTC 
phosphate from mannose-& manS Phosphomannomutase manS 62.5 394 100% 
phosphate 




ued 50.6 388 100% 
I<p(K9, CTC2242, 
ac id from UOP-e1ucase dehydroeenase 1084) 
• ATCC 43816amino-acid Ident ity percentaeeto species (serotype or stra'n) l isted in adjacent column. 
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Figure 3.3 
Jt2 : ATCC 43816 
Jt2: Chedid (AN : 021242) 
Jt2 : VGH525 (AN : AB371296) 
NO : 1084 (AN : CP003785)* 
1t5 : 
1t5 : VGH404 (AN : AB371292) 
K9 VGB484 (AN: AB371293) 
Ki4: VGH916 (AN: AB371294) 
Jt20 : NTOB-KP13 (AN: AB289648) 
1t54: NTtJ8-KP35 (AN: 0289650) 
1t57: Al142 (AN: AB334776) 
K62 : VG8689 (AN: AB371295) 
K62 : NTOB-KP53 (AN: AB290716) 
NT : A1517 (AN : AB334777) 
NO: Nlt245 (AN : AB371291) 
NO: Nlt29 (AN: AB371290) 
NO: NIt8 (AN : AB371289) 
NO : Kp13 (AN: IN 377737) 
NO : 8811286 (AN: CP003200)* 
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Figure 3.3 
Comparison of Sequenced K. pneumoniae CPS Clusters 
The K. pneumoniae ATCC 43816 CPS gene clusters compared to the CPS loci 
to ten K. pneumoniae serotypes (K1, K2, K5, K9, K14, K20, K52, K54, K~i7, and 
K62), one new serotype (NT) and seven undetermined serotypes (NO). The 
arrows with dotted lines belong to flanking genes of the CPS cluster. BluE! arrows 
represent highly conserved genes present in all CPS regions. Orange arrows 
correspond to genes of the highly conserved sequence, but presence and or 
absence depends on serotype. ATCC 43816 K2 serotype genes with high 
homology with other K2 serotype K. pneumoniae are represented by teal arrows. 
Black arrows correspond to gene wzx, which are highly variable at the se~uence 
level, but have an amino acid identity ~ 11 %. Red outline arrow represents 
pseudogenes. In ATCC 43816, the suggested names for the ORFs are based on 
amino-acid homology greater than 70%, with at least one annotated gene' from 
another CPS region. For the previously published CPS regions, names indicated 
above each gene correspond to annotations found in public databases, whereas 
names in italic under the genes are suggestions based on pairwise comparisons. 
* Re-annotation of NCBI data P: Promoter 
Image adapted from Ferve, et al. [91] 
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levels (Table 2). At the 3' end of the CPS cluster there are two genes (gnd and 
ugd) highly conserved between all sequenced strains with the gene ugd which is 
considered the last gene of the CPS cluster [91]. This data suggests that there is 
both a conserved and variable region of the CPS cluster. The conserved is seen 
in all serotype suggesting that the conserved genes are necessary for capsule 
production, while the variable region is serotype specific. 
3.6 Generating a capsular polysaccharide mutant 
Capsular polysaccharide has been demonstrated to be a critical factor in 
the virulence of K. pneumoniae in in vivo and in vitro models [72, 92]. Frcm this 
sequence data, we intended to generate a capsule mutant strain which mmoved 
the capsular polysaccharide from genes gafF to ugd. The development for the 
capsule mutant was designed to create an in-frame mutant, which fused the gafF 
start codon to the ugd stop codon deleting 23.7 -Kb of DNA. These two fragments 
were assembled flanking the zeocin antibiotic marker (Sh bfe gene) containing 
the foxP sites on either side. The foxP sites are recognized by Cre recombinase, 
which catalyzes the recombination of DNA between two foxP sites. The 
pJMW106-L\cap-floxZeo plasmid was then conjugated into K. pneumoniae ATCC 
43816 for two-stage allelic exchange mutagenesis. During the conjugation, a 
merodiploid K. pneumoniae strain was successfully generated; however, we had 
difficulty in generating a ZeoR clone that lacked the capsule cluster. Future efforts 
will be required to identify whether essential genes are present within the CPS 
cluster, whether other technical issues prevented the generation of this 2:3.7 Kb 
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region of DNA or the development of smaller multiple gene mutant or sinl~le gene 
mutant. 
3.7 Conclusion 
The CPS cluster investigated in this study has high homology to o'ther 
sequenced K2 serotypes suggesting that genetic information could be used in 
the future to predict serotype. The observation of a variable region located in the 




J774A.1 MACROPHAGE INVOLVEMENT IN K. PNEUMONIAE INFECTIONS 
4.1 Introduction 
Successful bacterial pathogens must be capable of circumventing their 
hosts' innate defenses, traffic to their preferred replicative niche and ultimately 
persist within their hosts. K. pneumoniae is widely considered to be an 
extracellular pathogen, though evidence for this characterization is circurlstantial 
[93, 94]. However, recent studies have demonstrated its ability to be internalized 
by epithelial cells and macrophages [47, 48, 61]. K. pneumoniae is know" to 
cause a wide range of infections and is commonly isolated from the lung~i. 
Pulmonary infections have been shown to result in dissemination from thl:! 
pulmonary airspace to the bloodstream. Alveolar macrophages reside in the 
interphase between air and lung tissue and provide the first line of cellular 
defense against microbes [95]. Previous research has demonstrated that alveolar 
macrophages contribute to the defense against K. pneumoniae infection !n the 
lungs [75]. Considering the fact that macrophages are the primary responders 
against pneumonia, we decided to study the relationship between K. pner.Jmoniae 
and J774A.1 murine macrophages. 
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4.2 Internalization of K. pneumoniae 
To investigate host-pathogen interaction of K. pneumoniae ATCC 43816, 
NTUH-K2044 and MGH 78578 we infected J774A.1 murine macrophage 
monolayers. To determine internalization of K. pneumoniae by J774A.1 cells, we 
used gentamicin protection assays (1 hour post-infection). The cells werE! 
challenged with an MOl of 10 for each strain of K. pneumoniae and 3 hours post-
infection cells were lysed and enumerations were taken. The macrophagl~s were 
observed to be viable by using immunofluorescence microscopy (data net 
shown) and our results demonstrated that all three strains of K. pneumoniae 
were able to be internalized by J774A.1 cells (Figure 4.1). For comparison, the 
uptake efficiencies of all three strains were assessed by percentage of in,)culum 
internalized by macrophage (i.e. survived gentamicin treatment by being 
internalized by macrophages). We observed the internalization of strain MGH 
78578 has the highest percentage inoculum uptake of 3.09%, with much lower 
rates of uptake observed for both ATCC 43816 (0.57%) and NTUH-K2044 
(0.17%). This data suggests that strain MGH 78578 is more readily phag()cytized 
by macrophages when compared to strains ATCC 43816 and NTUH-K2044 
(P<0.001, ***). These findings are consistent with the hypothesis that K. 
pneumoniae is an extracellular pathogen which represses phagocytosis to 
increase its virulence, as we have demonstrated that NTUH-K2044 and ATCC 
43816 are virulent in our respiratory murine disease model, while MGH 7B578 is 
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Internalization of Three K. pneumoniae Strains 
Percentage of bacterial inoculum internalized by J774A.1 cells in four 
independent (n=12) experiments represented by a whisker box plot. 7.5>:104 
cells per well murine macrophages were infected with K. pneumoniae at an Mal 
of 10 with strains ATCC 43816, NTUH-K2044, and MGH 78578. Gentam cin was 
added one hour post-infection to kill extracellular bacteria and bacteria uptake 
was assessed at 3 hours post-inoculation. Cells were lysed with 0.1 % Triton x-
100 and enumerated by plate counting and percentage of inoculum was 
calculated. Statistical analysis was carried out by one way ANOVA and Tukey 
posttest (P<0.05, *; P<0.01, **; P<0.001 ;***) (Limit of detection 0.0013% of 
inoculum). 
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4.3 Proliferation of K. pneumoniae 
We observed that K. pneumoniae strains could be internalized by J774A.1 
macrophages at different levels, and we decided to investigate whether the three 
K. pneumoniae strains exhibited different rates of proliferation within 
macrophages. We infected replicate sets of J774A.1 cells with the three ,I(. 
pneumoniae strains at an MOl of 10 and evaluated the ability of K. pneumoniae 
to proliferate within J774A.1 cells with enumerations taken at 3, 4.5, 6, 9 and 12 
hours post-infection. Our results show that all three strains can be internalized by 
3 hours by the J774A.1 macrophage as similar numbers were observed (Figure 
4.1 and Figure 4.2). However, both MGH 78578 and ATee 43816 showed an 
initial decrease in bacterial numbers followed by proliferation over the course of 
the infection (P<O.001, ***). The strain NTUH-K2044 was internalized as shown 
previously, but exhibited little growth over the course of the experiment (No 
significance). We also observed that ATee 43816 was taken up at a lowHr 
bacterial number than MGH, however at later time points, ATee 43816 
proliferated to similar bacterial numbers as MGH 78578. The low internalization 
and proliferation of all three strains suggests that macrophages may not be the 
preferred replicative niche for K. pneumoniae. 
4.4 Conclusion 
This work demonstrates that all three strains of K. pneumoniae can be 
internalized and persist within macrophages for prolong periods of time. The 
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Growth Curve of K. pneumoniae in Cultured Macrophage 
• ATCC MOl 10 
• NTUH MOl 10 
• MGH MOl 10 
Growth of internalized K. pneumoniae in J774A.1 cells over 12 hours. K. 
pneumoniae strains ATCC 43816, NTUH-K2044, and MGH 78578 were used to 
infect 7.5x1 04 cells per well in triplicate at an MOl of 10. After 1 hour, extracellular 
bacteria were killed with gentamicin. At time points of 3,4.5, 6, 9 and 12 hours 
post-inoculation, samples were lysed with 0.1 % Triton X-100 and enumerated by 
plate counting. This figure is a representative of three independent trails with all 
displaying similar results. The data is representative of at least three replicate 
trials with plots of mean and standard error for each data point. Statistical 
analysis was carried out by one way T-test (P<0.05, *; P<0.01 , **; P<0.001 ;***, 
P<0.0001 ;****) (Limit of detection 0.0013% of inoculum). 
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lack of in vivo pathogenicity in the pulmonary infection model [84], whereas both 




ENGINEERING OF A LUMINESCENT K. PNEUMONIAE STRAIN 
5.1 Introduction 
Bioluminescence reporter systems have been engineered into many 
species of bacteria to allow for the production of light to be used to monitor 
disease processes in living systems [96-104]. The engineering of this bioreporter 
into K. pneumoniae ATCC 43816 would enable us the ability to perform real-time 
quantification of viable bacteria within a host. One of the most frequently used 
bioluminescent reporter systems used in bacteria is the luxCDABE operon of 
Photorhabdus luminescens which is a bacterial specific system with many 
advantages over eukaryotic luciferases as the luxCDABE operon produces both 
the luciferase enzyme and the substrates required for light production, 
eliminating the need to provide substrate exogenously to the assay [105]. 
The single transcriptionalluxCDABE unit contains luxA and luxB genes 
coding for the a- and r3-subunits that form a heterodimer luciferase [106]. The 
luxCDE products work as a multienzyme fatty acid reductase complex required 
for regeneration of the long-chain fatty aldehydes [105]. The long-chain fatty 
aldehydes are subsequently oxidized by the luciferase heterodimer, with energy 
supplied by flavin mononucleotide (FMNH2), to produce a photon of blue/green 
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light (-500nm)[1 05]. Unlike eukaryotic luciferases, bacterialluciferase system 
requires no additional exogenous substrates to generate bioluminescence during 
both in vitro and in vivo assays. This makes the lux operon an ideal system for 
real time monitoring of bacteria. 
5.2 Generating a /ux+ K. pneumoniae strain 
ATCC 43816 strain is a well-studied K. pneumoniae strain, capable of 
causing respiratory disease in animal models. We engineered the luxCDABE 
operon into this strain for use in both in vitro and in vivo studies. The ATCC 
43816 strain was engineered to produce constant, stable luminescence from the 
luxCDABE operon and we used allelic exchange mutagenesis to insert the 
operon into the chromosome. The insertion site of the lux operon was selected 
based on the observation that a related Klebsiella strain possesses a nitrogen 
fixation operon located between the arsenical resistance operon (fusA) and the 
spore permease transport system (yeeF) which was found to be a conserved 
region in other strains of K. pneumoniae (Figure 5.1). Therefore, this site was 
selected for the insertion of the lux operon to minimize the impact on other 
genetic systems or virulence. We cloned homologous portions of DNA to 
facilitate allelic exchange including a portion of fusA and the neighboring 
hypothetical gene (Figure 5.1, left side) and part of the yeeF (Figure 5.1, right 
side). These two fragments were assembled to flank the lux operon in pGSVS 
along with the rplU promoter, which was used to constitutively express the lux 
operon. The rplU gene is a subunit of the 50S ribosomal subunit of protein L21 




Arsenical resistance operon 




Scale representation of JSKP001 genetic organization . Nucleotide sequence of 
the P. luminescens lux operon is given in GenBank (AN: M90093). lux operon is 
flanked at the 5' end Gene fusA and a hypothetical gene (arsenical resistance 
operon) and at the 3' end yeeF (spore permease transport system). The rplU 
promoter was cloned upstream of the luxCDABE operon (purple rectangle). 
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ribosomal protein promoter will allow the lux operon to be constitutively 
transcribed whenever the bacteria are metabolically active. The zeocin antibiotic 
marker (Sh ble gene) was cloned at the end of the luxE gene with flanking 10xP 
(flox) sites. These sites, known as the 10xP sequences, contain specific binding 
sites for Cre that surrounds the two directional core 10xP sequences and allowing 
for excision by recombination. The pGSVS2-Kp ATCC-PrpIU-lux-floXZeo plasmid 
was then conjugated into K. pneumoniae ATCC 43816 for two-stage allelic 
exchange mutagenesis, producing the luminescent strain WKP001. The removal 
of the zeocin antibiotic marker was performed done by introducing the vector 
pKSVS2-PtoIC-cre-gaIF into WKP001. Cre recombinase was transiently 
expressed to excise the antibiotic marker, while leaving the PrplU-lux construct in 
the chromosome. The sacB-marked Cre expression vector was selected against 
using sucrose, and the resulting strain was named JSKP001. 
5.3 In vitro bioluminescence of K. pneumoniae JSKP001 
To investigate whether the light production from JSKP001 correlates with 
bacterial numbers, we cultured JSKP001 in TSBDC broth media and examined 
both light production and bacterial numbers at multiple time points. The bacteria 
were grown with shaking in LB overnight and subcultured into TSBDC for four 
hours (Figure 5.2A). TSBDC is a metal-depleted media which we routinely use to 
mimic the metal-limited environment of the host. We observed statistically 
significant exponential growth for the first three and a half hours of the broth 
growth with evidence of stationary phase beginning at four hours. A trend line 
was plotted through the first 3.5 hours of growth and we calculated a doubling 
S2 
time of 52.9 minutes. This doubling time is greatly reduced from K. pneumoniae 
grown in LB which has a double time of 13 minutes [30], suggesting that the 
metabolic state of the bacteria may be significantly different in LB and TSBDC. 
During the time course of the TSBDC growth, we also measured 
bioluminescence (counts per second (cps)) bacterial number's. The cps/CFU 
ratio decreased after the first hour with statistically significant a decrease in light 
emitted per bacteria over the course of the experiment. At three hours, the 
bioluminescence resumed an altered correlation for the last hour (Figure 5.2A). 
This suggests that JSKP001 grown in LB may have been more metabolically 
active than in TSBDC and that a transition to an altered luminescent activity after 
three hours growth in TSBDC reflects a change in the metabolic activity of the 
bacteria. Alternatively, it is possible that the PrplU promoter may not be 
constitutive in TSBDC. 
Because the metabolic activity may impact the magnitude of light 
production per bacteria, we hypothesized that altering the competition for energy 
within the bacteria could impact light production. Therefore, we investigated how 
arresting new protein synthesis with sub-lethal concentrations of chloramphenicol 
[107] affects bioluminescence of JSKP001. We grew JSKP001 in LB overnight 
and then subcultured into TSBDC, for one hour before adding chloramphenicol. 
As expected, bacterial growth was repressed by chloramphenicol and bacterial 
numbers remained unchanged throughout the experiment (Figure 5.2B). Unlike 
previous trials in which we had a rapid decrease in the emitted light per bacteria 
(Figure 5.2A), we observed that the cps/CFU dramatically increased in a 
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Figure 5.2 
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K. pneumoniae strain JSKP001 was grown in TSBDC broth for 4 hours. Every 30 minutes, a 100 IJI volume was 
drawn from the bacterial culture for a bioluminescent reading and bacterial enumeration. The exponential growth is 
indicated with a trend line and used to determine doubling time (A) . In a separate experiment, chloramphenicol 
antibiotic was added to the TSBDC broth 1 hour after initiating the experiment. A trend line was plotted to show 
bacterial growth was repressed (B). Both experiments were performed in triplicate. Each data point is the mean 
and standard error. Statistical analysis was carried out by one way T-test from the first to last data points of the 
growth study (P<0.05, *; P<0.01, **; P<0.001 ;***). (Limit of detection 100 CFU of inoculum; Limit of detection 355 
cps). 
statistically significant manner after the addition of chloramphenicol (Figure 
5.28). This level of light production remained high throughout the course of the 
experiment and only began to decrease a later time points. This data suggests 
that most energy-requiring bacterial proteins have relatively short half-lives which 
break down and leave excess energy for the Lux proteins. Conversely, the data 
suggests that the Lux proteins remain stable for the period of observation with 
high level production of light for four hours. The elevated cps/CFU suggests that 
typically the metabolic activity in bacterial cells leaves little energy available for 
the luciferase activity. However, we hypothesize that blockage of protein 
synthesis led to rapid turnover of many host proteins, decreasing the competitive 
demand for energy of the relatively stable Lux proteins. 
5.4 Intracellular Survival of /ux+ K. pneumoniae 
We decided to evaluate the ability of K. pneumoniae strain JSKP001 to 
produce light in a potentially important host-pathogen interaction model. To 
investigate whether the light production from JSKP001 correlates with bacterial 
numbers in an intracellular niche, JSKP001 was examined using our previous 
gentamicin protection assay of cultured macrophages. We infected replicate sets 
of J774A.1 cells with JSKPOO 1 at an MOl of 10 and bioluminescence was 
measured by the plate reader immediately before harvesting the samples for 
bacterial enumeration at 3, 4.5, 6, 9 and 12 hours post-infection (Figure 5.3). As 
previously observed (Figure 4.1), approximately 0.7% of the K. pneumoniae 
JSKP001 (ATCC 43816 derivant) inoculum was taken up by the J774A.1 
macrophages, with statistically significant increase in bacterial numbers over the 
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Intracellular Survival of K. pneumoniae JSKP001 in J774A.1 Cell Line 
K. pneumoniae strain JSKP001 was used to infect murine J774A.1 cell line 
(7.5x104 cells/well) in triplicate at an MOl of 10. After 1 hour, extracellular 
bacteria were killed with gentamicin. At time points of 3,4.5,6,9 and 12 hour 
post-inoculation, the light production of the sample sets as measured. The cells 
were washed, then lysed using 0.1% Triton X-100, and the bacteria were 
enumerated by plate counting. CFU/well was plotted as a function of time for 
JSKP001. Bioluminescence was measured prior to cell lysing and cps/well was 
plotted as a function of time. Each data point is the mean and standard error. 
Statistical analysis was carried out by one way T -test comparing the first and last 
data points (P<0.05, *; P<0.01 , **; P<0.001 ;***) (Limit of detection 0.0013% of 
inoculum; Limit of detection 345 cps) . 
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course of the experiment (Figure 5.3). Initially, the JSKP001 strain produced light 
consistent with bacterial numbers, however after four and half hours the 
luminescence per bacteria decreased in a statically significant manner over the 
course of the experiment. These findings suggest that JSKP001 produces light 
during host-pathogen interaction in the macrophage infection model; however, 
the decrease in cps readings suggests that Lux proteins have a reduced 
availability of energy for bacteria which persist in intracellular niches. 
5.5 Conclusion 
In this study, we developed a bioluminescent strain of K. pneumoniae by 
engineering the luxCDABE operon into the chromosome. Lux proteins may be 
more stable than other bacterial proteins, but appear to compete for the same 
energy source as host bacterial proteins, with the potential for significant 
variation in the availability of energy from one environment to another. Future 
studies will be required to confirm by Western blot whether the Lux proteins 
indeed possess longer half-lives than most host proteins. This study provided 
evidence that K. pneumoniae might enter a dormant stage of reduced metabolic 
activity when internalized by macrophages, or that the rplU promoter may be 




The CPS is one of the best characterized virulence factors of K. 
pneumoniae as it facilitates resistance to complement-mediated bacteriolysis and 
phagocytosis [48]. Studies have indicated that capsule-negative strains are 
highly susceptible to rapid clearance in in vitro and in vivo assays which indicates 
that CPS has a major impact on disease [61, 7'5, 92, 108]. Because the CPS of 
K. pneumoniae is an important virulence factor, one of our objectives was to 
completely sequence and preform bioinformatics analysis of the ATCC 43816 
capsule biosynthetic cluster. Our results added to a growing list of genetically 
characterized capsular clusters and revealed high sequence homology among 
the K2 serotypes. Similar trends of high sequence homology are observed in four 
additional serotypes that have multiple sequenced strains [91]. This information 
suggests that if a sufficient number of sequenced and well characterized CPS 
biosynthetic clusters were available, that genetic data could be used to predict 
the serotype for Klebsiella. For example, the sequenced strain KCTC 2242 has 
not yet been serotyped; however, the strain has high genetic homology to the 
sequenced CPS clusters of K2 serotype and strongly suggests from genetics that 
KCTC 2242 is a K2 serotype strain, which could be demonstrated in future 
studies. Additionally, serotyping may encounter technical issues, as in the 
58 
instance where serotyping efforts of the K. pn€,umoniae strain KpL 1 were not 
previously successful in spite of the fact that it possesses the magA, gmd and 
wcaG genes similar to the K1 capsular clusters [109]. 
Our data is adding to the growing set of evidence that every sequenced 
strain from the Klebsiella genus has a highly conserved set of CPS genes 
suggesting that capsule is a critical structure present in all Klebsiella. The 
capsule biosynthetic cluster has 15 to 25 genes that are required for capsule 
synthesis and of these, eight are conserved with high sequence homology 
amongst K. pneumoniae subspecies pneumoniae, rhinoscleroma, oxytoca and K. 
variicola [91]. Six of these genes cluster together in what appears to be a 
transcriptional cluster at the 5' end of the CPS cluster and are involved in 
polymerization control. They are thought to form a membrane pore through which 
translocation of the CPS product is moved from the inner membrane to the cell 
surface for capsule assay [110]. Single gene mutants within these genes lead to 
acapsular phenotypes with loss of high-molecular weight extracellular polymer 
with the accumulation of the CPS precursors in the periplasm of the bacteria 
[111]. Two additional conserved genes (gnd and ugd) are located downstream of 
the variable region of the CPS biosynthetic cluster. The gnd gene encoding an 
NADP-dependent 6-phosphogluconate dehydrogenase is involved in the pentose 
phosphate pathway which converts 6-phosphogluconate into ribulose 5-
phosphate and produces NADPH for reductive biosynthesis and nucleotide 
biosynthesis [112]. The ugd gene encodes UDP-glucose dehydrogenase, which 
converts UDP-glucose into UDP-glucuronic acid, the substrate for capsule 
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synthesis [113]. The high degree of conservation of the core set of eight genes 
amongst members of the Klebsiella genus suggests a common ancestry of these 
genes and conserved mechanism of capsule assembly. Homologues of these 
eight conserved genes are also found in a variety of intestinal flora bacteria, such 
as Enterobacter aerogenes, Salmonella enterica, Escherichia coli, Serratia 
marcescens and Shigella boydii and potentially amongst other members of the 
Enterobacteriaceae family [114-118]. 
The genetic arrangement of the CPS cluster has a genetically variable 
CPS locus which is thought to contribute to the diversity of the capsular 
polysaccharide serotype of K. pneumoniae and is flanked by conserved genes. 
Because of this conservation found within the Enterobacteriaceae family there 
may be exchange of the CPS using homologous recombination in the intestine. 
The intestine has been previously demonstrated to be a potential site for 
interchange of genetic material as K. pneumoniae has been observed to transfer 
antibiotic resistant genes to E. coli in the mouse intestine [119]. While 
homologous recombination of large segments of the CPS cluster might happen 
at very low frequency, there is evidence for horizontal gene transfer of capsule 
genes amongst members of the Enterobacteriaceae family as observed by a high 
genetic similarity of the capsule clusters of E. coli K30 and K. pneumoniae K20 
suggesting recent exchange of CPS clusters between these two species [120, 
121]. Additionally, the capsule of E. coli K42 was observed to have a 
serologically identical capsule as a K. pneumoniae K63 strain [113, 122], 
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supporting the evidence that members of the Enterobacteriaceae family may 
exchange CPS gene clusters, potentially in the! intestine. 
The CPS of K. pneumoniae may be one factor in directing host niche 
specificity for different K. pneumoniae strains. It has been shown that multiple 
serotypes infect different niches. For example, serotypes 21, 33 and 69 are 
predominately found causing infections in the lJrinary tract, while serotypes 30 
and 31 predominately are found causing wound infection [123]. However, of the 
80 different serotypes identified, most reports indicate that K1 and K2 serotypes 
are amongst the most common isolated from patients and additionally are the 
most invasive strains [123-127]. It has been suggested that the degree of 
virulence conferred by a particular K antigen of K. pneumoniae might be 
connected to the man nose content of the CPS. Capsular types associated with 
low virulence, such as the K7 or K21a antigen, contain sequences of mannose-a-
2/3-mannose or L-rhamnose-a-2/3-L-rhamnose which are recognized by a 
surface lectin of macrophages [128-130]. Macrophages with the mannose-a-2/3-
mannose-specific lectin or man nose receptor recognize, ingest, and 
subsequently kill K. pneumoniae CPS serotypes containing mannose. In 
contrast, strains with theK2 serotype, which lack the man nose repeating 
sequence, are not phagocytized [131]. Thus, K. pneumoniae CPS may play an 
important role in directing the preferred host niGhe, in part mediated by 
immunomodulation. 
Macrophages are considered major effector cells of host defense against 
respiratory tract infections by virtue of their potent phagocytic properties. In 
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addition, macrophages may regulate the host inflammatory response to infection 
by the production of cytokines [132]. Alveolar rnacrophages are important for the 
rapid elimination of K. pneumoniae from respiratory tract and by orchestrating the 
inflammatory response against this pathogen [133]. We analyzed the interplay 
between K. pneumoniae strains and J774A.1 macrophage cells to get a better 
understanding of the host response to K. pneumoniae infections. Our results 
demonstrated that K. pneumoniae can be internalized by macrophages at low 
levels and survive for prolonged periods of time. However, some strains of K. 
pneumoniae may not proliferate in macrophages at high levels typically observed 
for intracellular bacterial pathogens, which suggests K. pneumoniae may excel 
as an extracellular pathogen. However, macrophages might be a potential niche 
for chronic persistence in sublethal infections. There is clinical evidence that K. 
pneumoniae is capable of causing chronic disease with frequent and recurrent 
manifestation in the liver up to ten year post infection [134, 135]. Recurrent 
infection is also seen in other bacteria such as Mycobacterium tuberculosis, 
which colonize macrophages, enter a latent phase, and then causes a 
subsequent acute disease [136]. 
We engineered a bioreporter into K. pneumoniae ATCC 43816 to enable 
us the ability to perform real-time quantification of viable bacteria. While 
investigating how light production from JSKP001 correlated to bacterial numbers, 
we first observed that bacteria cultured in TSBDC had a relatively high level of 
light emitted per bacteria (1.167 x 10-3 cps/CFU), but after about three hours, the 
bacteria transitioned to a much reduced light emission per bacteria (1.713 x 10-6 
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cps/CFU) (Figure 6.1A). This brought up several questions for us. Was the 
transcriptional regulation of the rplU promoter Gausing reduced expression of Lux 
proteins or was the efficiency of the enzymes negatively impacted by the 
metabolic state of the bacteria? Because the metabolic activity may impact the 
magnitude of light production per bacteria, we altered the competition for energy 
within the bacteria by stopping new protein synthesis. We observed that the Lux 
proteins were competing for the same energy source as host bacterial proteins 
(ATP) (Figure 6.1), but also observed that the ILux proteins appear to have a 
longer half-life than most host proteins and are! able to access additional energy 
for light production in the absence of competition. When examining the products 
needed for light production, ATP is used to regenerate long chain fatty aldehydes 
and the TCA cycle to regenerate FMNH2 (Figure 6.1 B). Both products are 
oxidized by the LuxAB dimer in the presence of oxygen to product light (Figure 
6.1 B). Because the Lux proteins appear to be competing for the same energy 
source there is a potential for variation in the availability of energy when K. 
pneumoniae goes from one environment to another causing an alteration in 
metabolism within the bacteria. We have not addressed the possibility that the 
rplU promoter may not be constitutively expressed in macrophages which we 
could investigate using RT-PCR studies. 
An original aim of this thesis project was to bridge the two major aims by 
developing a capsule mutant and use the luminescent tool to monitor disease 
progression for the capsule mutant in the respiratory disease model. We were 
unsuccessful in generating a capsule mutant, thus future experiments will identify 
63 
Figure 6.1 




Summation of Figure 5.2 
Late TSBDC TSBDCCm 
~~ 
luxCDABE 
1. 713 X 10.6 cps/CFU 
Schematic diagram of K. pneumoniae cells in TSBDC during different time 
points and with or without chloramphenicol. Blue wavy lines represent mRNA 
transcript of the /uxCDABE operon. The red/orange circles represent relative 
numbers of LuxAB protein dimer and purple shape represent relative numbers of 
bacterial host proteins. ATP is represented at yellow stars and lime green around 
cells is relative production of light produced by LuxAB proteins (A) . The 
mechanism of light production is a complex series of energy requiring 
oxidation/reduction reactions where the LuxAB protein dimer requires energy for 
the production of light in the form of both ATP and NADH/NADPH from the TCA 
cycle (B). 
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whether essential genes are present within the CPS cluster or whether other 
technical issues prevented the generation of this 23.7 Kb region of DNA. Future 
studies will be needed to demonstrate that the transfer of capsule biosynthetic 
clusters can be shared between the Enterobacteriaceae family. Additionally, 
future studies will also be required to characterize the role of macrophages in 
recurrent K. pneumoniae disease. We are also interested in examining whether 
bioluminescence can be used to monitor disease progression in animal models. 
Some of these future directions are already being performed within the lab as the 
animal studies are currently on going in the laboratory and raise good evidence 
that the there is a correlation between luminescence and bacterial numbers 
within animal tissues. 
In conclusion, we have genetically characterized the K2 serotype capsular 
polysaccharide cluster from ATCC 43816. Comparative genomics indicate that 
there are both conserved and variable regions within all sequenced capsular 
polysaccharide cluster of K. pneumoniae which could provide exchange of the 
serotype specific genes through the mechanism of horizontal gene transfer. Our 
understanding from our macrophage studies that K. pneumoniae prefers to be an 
extracellular pathogen as it enters a novel latent phase within the macrophages. 
Furthermore, we validated a diagnostic imaging tool for K. pneumoniae to 
support macrophage internalization studies and the tools developed in these 
studies is currently being used to support animal respiratory disease model. Plus, 
additional future studies will be needed to demonstrate that the transfer of 
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